Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Piper Jaffray Raises Price Target on Abiomed (ABMD) Following 1Q16
August 5, 2015 10:15 AM EDTPiper Jaffray reiterated a Neutral rating on ABIOMED (NASDAQ: ABMD), and raised the price target to $85.00 (from $71.00), following 1Q16 results. Abiomed reported F1Q16 revenue of $73.4M vs. consensus $66.0M. Management plans to provide a business update including a 5-year plan and pipeline update at its August 11 investor... More
Abiomed (ABMD) Tops Q1 EPS by 12c
August 4, 2015 7:03 AM EDTAbiomed (NASDAQ: ABMD) reported Q1 EPS of $0.20, $0.12 better than the analyst estimate of $0.08. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $66.27 million.
Abiomed sees FY2015 revenue of $300-310 million, versus prior guidance of $285-295 million and the consensus of $292.4... More
